Polyq Diseases | List of Frontiers open access articles

Review

Published on 15 May 2018

Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

in Brain Disease Mechanisms

Chunchen Xiang
Shun Zhang
Xiaoyu Dong
Shuang Ma
Shuyan Cong

Frontiers in Molecular Neuroscience

doi 10.3389/fnmol.2018.00153

8,725 views
31 citations

Review

Published on 12 Feb 2021

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases

in Neurodegeneration

Eiko N. Minakawa
Yoshitaka Nagai

Frontiers in Neuroscience

doi 10.3389/fnins.2021.621996

16,077 views
45 citations

Review

Published on 14 Sep 2022

A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases

in Molecular Signalling and Pathways

Sean L. Johnson
Wei-Ling Tsou
Matthew V. Prifti
Autumn L. Harris
Sokol V. Todi

Frontiers in Molecular Neuroscience

doi 10.3389/fnmol.2022.974167

6,001 views
21 citations

Review

Published on 31 Mar 2017

Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases

in Molecular Signalling and Pathways

Fabio Sambataro
Maria Pennuto

Frontiers in Molecular Neuroscience

doi 10.3389/fnmol.2017.00082

14,838 views
55 citations

Mini Review

Published on 23 Mar 2017

Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch

in Neurodegeneration

E. F. E. Kuiper
Eduardo P. de Mattos
Laura B. Jardim
Harm H. Kampinga
Steven Bergink

Frontiers in Neuroscience

doi 10.3389/fnins.2017.00145

10,010 views
57 citations

Review

Published on 01 Jul 2021

Juvenile Huntington’s Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data

in Stem Cell Research

Karolina Świtońska-Kurkowska
Bart Krist
Joanna Delimata
Maciej Figiel

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.642773

8,760 views
17 citations

Review

Published on 06 Oct 2020

Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?

in Cellular Neuropathology

Inês Barros
Adriana Marcelo
Teresa P. Silva
João Barata
David Rufino-Ramos
Luís Pereira de Almeida
Catarina O. Miranda

Frontiers in Cellular Neuroscience

doi 10.3389/fncel.2020.584277

5,918 views
8 citations

Articles

Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases

A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases

Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases

Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch

Juvenile Huntington’s Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data

Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?